Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy

Abstract

Systemic lupus erythematosus(SLE) is a chronic, inflammatory autoimmune disease that may involve multiple organ systems. Treatment consists of immunosuppression, cytotoxic treatment, plasmapheresis and immunoglobuline therapy. Treatment of patients refractory to standard treatment approaches is difficult and results are poor. We describe a 39-year old patient with SLE sufferingfrom grand mal epilepsy due to cerebralvasculopathywith positivelupus anticoagulant, who was refractory to standard treatment modalities. The patient was treated with the anti-CD20 monoclonal antibody rituximab (375 mg/m² ×4, repeated at weekly intervals). Rituximab applications were delivered in October 2000, March 2001 and October 2001. Since March 2002 she has received maintenance therapy with rituximab 375 mg/m² every three months. A second female with refractory SLE was treated successfully in April 2002 and receives maintenance therapy every three months. Both patients responded well to rituximab therapy. The first patient showed a major improvement of her clinical condition, and 30 months after the beginning of the rituximab therapy she is free of any symptoms. inflammation parameters, ANA and lupus anticoagulantdeclined significantly after the treatment. The clinical conditionof the second patient improved dramatically, all inflammation parameters normalized and her circulating immunocomplexes disappeared. In conclusion, rituximab maintenance treatment may be a new effective therapy in SLE.

Keywords

maintenance therapy rituximab SLE

Get full access to this article

View all access options for this article.

References

Boumpas DT , Austin HA III , Fessler BJ et al. Systemic lupus erythematosus: Emerging Concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary and hematologic disease . Ann Intern Med 1995; 122: 940-950 .

Boumpas DT , Fessler BJ , Austin HA III et al. Systemic lupus erythematosus: Emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity, and mortality and pathogenesis . Ann Intern Med 1995; 123: 42-53 .

Mills JA. Systemic lupus erythematosus . N Engl J Med 1994; 330: 1871-1879 .

Asherson RA , Khamashta MA , Ordi-Ros J et al. The “primaryfiantiphospholipid syndrome: Major clinical and serological features . Medicine 1989; 68: 366-374 .

Santoro SA. Antiphospholipidantibodies and thromboticpredisposition: Underlying pathogenetic mechanisms . Blood 1994; 83: 2389-2391 .

Roubey RA. Autoantibodies to phospholipid-bindingplasma proteins: A new view of lupus anticoagulants and other “antiphospholipidfiautoantibodies . Blood 1994; 84: 2854-2867 .

Ginsberg JS , Wells PS , Brill-Edwards P et al. Antiphospholipid antibodies and venous thromboembolism . Blood 1995; 86: 3685-3691 .

Sibley JT , Olszynski WP , Decoteau WE , Sundaram MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus . J Rheumatol 1992; 19: 47-52 .

Wong KL , Woo EK , Yu YL , Wong RW. Neurologic manifestations of systemic lupus erythematosus: A prospective study . Q J Med 1991; 81: 857-870 .

10.

Futrell N , Schultz LR , Millikan C. Central nervous system disease in patients with systemic lupus erythematosus . Neurology 1992; 42: 1649-1657 .

11.

Bruyn GA. Controversies in lupus: Nervous system involvement . Ann Rheum Dis 1995; 54: 159-167 .

12.

Petri M. Pathogenesis and treatment of the antiphospholipid antibody syndrome . Med Clin North Am 1997; 81: 151-177 .

13.

Drenkard C , Villa AR , Alarcon-Segovia D , Perez-Vazquez ME. influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus . J Rheumatol 1994; 21: 1067-1072 .

14.

Johnson RT , Richardson EP. The neurologic manifestations of systemic lupus erythematosus: A clinico-pathological study of 24 cases and review of the literature . Medicine 1968; 47: 337-369 .

15.

Bluestein HG. Neurocytotoxic antibodies in the serum of patients with SLE . Proc Natl Acad Sci USA 1978; 75: 3965-3969 .

16.

Toubi E , Khamaschta MA , Panarra A et al. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus . Am J Med 1995; 99: 397-401 .

17.

Petri M , Roubenoff R , Dalla GE et al. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus . Lancet 1996; 348: 1120-1124 .

18.

Herranz MT , Rivier G , Khamashta MA et al. Association between antiphospholipidantibodies and epilepsy in patients with SLE . Arthritis Rheum 1994; 37: 568-571 .

19.

Traynor AE , Schrieder J , Rosa RM et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haematopoietic stem-cell transplantation: a phase I study . Lancet 2000; 356: 701-707 .

20.

Khamashta MA , Ruiz-Irastorza G , Hughes GR. Therapy of systemic lupus erythematosus: new agents and new evidence . Expert Opin Investig Drugs 2000; 9: 1581-1593 .

21.

McLaughlin P , Hagemeister FB , Grillo-Lopez AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial . Semin Oncol 1999; 26(5 Suppl 14): 79-87 .

22.

Czuczman MS , Grillo-Lopez AJ , White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy . J Clin Oncol 1999; 17: 268-276 .

23.

Ratanatharathorn V , Carson E , Reynolds C et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease . Ann Intern Med 2000; 133: 275-279 .

24.

Lee EJ , Kueck B. Rituxan in the treatment of cold agglutinin disease . Blood 1998; 92(9): 3490-3491 .

25.

Levine TD , Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab . Neurology 1999; 52: 1701-1704 .

26.

Weide R , Heymanns J , Köppler H. The polyneuropathy associated with Waldenström’s macroglobulinaemia can be treated effectively with chemotherapy and the anti-CD20 monoclonal antibody rituximab . Br J Haematol 2000; 109: 838-841 .

27.

Odendahl M , Jacobi A , Hansen A et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus . J Immunol 2000; 165: 5970-5979 .

28.

Arce E , Jackson DG , Gill MA , Bennett LB , Banchereau J , Pascual V. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus . J Immunol 2001; 167: 2361-2369 .

29.

Weide R , Heymanns J , Köppler H. Successful treatment of systemic lupus erythematosus with rituximab . Onkologie 2001; 24(6): 479-479 .

30.

Leandro MJ , Edwards JC , Cambridge G , Ehrenstein MR , Isenberg DA. An open study of B-lymphocyte depletion in systemic lupus erythematosus . Arthritis Rheum 2002; 46: 2673-2677 .

31.

Kneitz C , Wilhelm M , Tony HP. Effective B cell depletion with rituximab in the treatment of autoimmune diseases . Immunobiology 2002; 206: 519-527 .